Invivyd Pops As COVID Antibody Marches Toward Pivotal Readout
Invivyd Inc. (NASDAQ: IVVD) jumped roughly 25% after investors digested fresh progress on its late‑stage COVID‑19 prevention program for monoclonal antibody VYD2311. The move comes as the company upsizes its Phase 3 DECLARATION trial and reinforces the cash runway behind a broader infectious‑disease antibody pipeline.
What moved the stock
Invivyd said a pre‑specified sample‑size re‑estimation in the DECLARATION trial showed enough COVID‑19 events have accumulated to support anticipated efficacy levels, even with about half the base study still to go. Management is adding about 500 subjects (on top of ~1,800) and now guides top‑line data to the third quarter of 2026, only about two months later than previously expected.
The study is testing single and monthly intramuscular doses of VYD2311 for pre‑exposure prophylaxis versus placebo over 90 days, and the antibody already carries FDA Fast Track status. Invivyd is also aligning with the agency on pediatric plans (the DRUMMER trial) and exploring VYD2311 in Long COVID and post‑vaccine syndromes via the planned SPEAR study, contingent on DECLARATION success.
Balance sheet and pipeline context
Under the surface of the 25% spike, IVVD is still down about 45% year‑to‑date, even after gaining more than 150% over the past year, highlighting how volatile sentiment has been around the name. Financially, 2025 net product revenue (driven by PEMGARDA) more than doubled to about 53 million dollars, operating expenses fell sharply, and cash and equivalents climbed to roughly 227 million dollars after over 200 million in second‑half financing—giving Invivyd meaningful runway into and beyond the VYD2311 readout.
For investors, the bull case is that strong DECLARATION data plus follow‑on pediatric and Long COVID indications could turn IVVD into a durable antibody platform story; the bear case is that the stock screens as overvalued on some fair‑value models and remains highly dependent on one pivotal COVID program in a market where vaccine and antibody demand has been choppy.
